The Chicago Entrepreneur

European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai

The committee said Leqembi’s effect on delaying cognitive decline does not outweigh “the risk of serious side effects associated with the medicine.”

Previous post Warner Bros. Discovery is counting on deregulation to unlock media deals — if there’s even appetite
Next post LVMH CEO Bernard Arnault says Olympics sponsorship honors the spirit of France